ADVERTISEMENT
Flu
Intranasal H5N1 vaccine experts discuss Phase I data, mucosal immunity, BARDA/NIH funding realities and how BlueWillow Biologics' NanoVax platform could strengthen global pandemic flu preparedness and respiratory defenses.
ADVERTISEMENT
Intranasal H5N1 vaccine experts discuss Phase I data, mucosal immunity, BARDA/NIH funding realities and how BlueWillow Biologics' NanoVax platform could strengthen global pandemic flu preparedness and respiratory defenses.